[go: up one dir, main page]

WO2009111169A3 - Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire - Google Patents

Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire Download PDF

Info

Publication number
WO2009111169A3
WO2009111169A3 PCT/US2009/034466 US2009034466W WO2009111169A3 WO 2009111169 A3 WO2009111169 A3 WO 2009111169A3 US 2009034466 W US2009034466 W US 2009034466W WO 2009111169 A3 WO2009111169 A3 WO 2009111169A3
Authority
WO
WIPO (PCT)
Prior art keywords
pkc
compositions
delta
methods
delta modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/034466
Other languages
English (en)
Other versions
WO2009111169A2 (fr
Inventor
Keith Wayne Ward
Srini Venkatesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch and Lomb Inc filed Critical Bausch and Lomb Inc
Publication of WO2009111169A2 publication Critical patent/WO2009111169A2/fr
Publication of WO2009111169A3 publication Critical patent/WO2009111169A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des compositions pour traiter ou lutter contre une dégénérescence d'au moins un composant du système nerveux optique humain, qui comprend un modulateur de la protéine kinase Gdelta (« PKC-delta »). Un tel modulateur PKC-delta peut être un composé qui empêche, réduit, ou interfère sensiblement avec une activité d'une cascade de signalisation cellulaire mettant en jeu PKC-delta ou une activation de PKC-delta. Les compositions peuvent également comprendre un médicament anti-inflammatoire. De telles compositions peuvent être administrées pour fournir une neuroprotection à un patient souffrant d'une maladie oculaire, telle qu'un glaucome, une dégénérescence maculaire liée à l'âge (AMD), une rétinopathie diabétique (DR), ou une rétinite pigmentaire.
PCT/US2009/034466 2008-02-29 2009-02-19 Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire Ceased WO2009111169A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3258408P 2008-02-29 2008-02-29
US61/032,584 2008-02-29

Publications (2)

Publication Number Publication Date
WO2009111169A2 WO2009111169A2 (fr) 2009-09-11
WO2009111169A3 true WO2009111169A3 (fr) 2010-02-25

Family

ID=40762329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/034466 Ceased WO2009111169A2 (fr) 2008-02-29 2009-02-19 Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire

Country Status (1)

Country Link
WO (1) WO2009111169A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795640B2 (en) 2011-12-22 2014-08-05 Mary Kay Inc. Lip formulation
ITUB20169937A1 (it) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006516A1 (fr) * 2000-07-18 2002-01-24 Joslin Diabetes Center, Inc. Procedes de modulation de l'angiogenese
WO2007035782A2 (fr) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Peptide modulateurs de la proteine kinase c de l'angiogenese
WO2008079980A1 (fr) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibiteurs de la protéine kinase c-delta pour le traitement du glaucome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006516A1 (fr) * 2000-07-18 2002-01-24 Joslin Diabetes Center, Inc. Procedes de modulation de l'angiogenese
WO2007035782A2 (fr) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Peptide modulateurs de la proteine kinase c de l'angiogenese
WO2008079980A1 (fr) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibiteurs de la protéine kinase c-delta pour le traitement du glaucome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AZADI S ET AL: "Up-regulation and increased phosphorylation of protein kinase C (PKC) delta, mu and theta in the degenerating rd1 mouse retina", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 31, no. 4, 1 April 2006 (2006-04-01), pages 759 - 773, XP024908201, ISSN: 1044-7431, [retrieved on 20060401] *
GSCHWENDT M ET AL: "Rottlerin, a Novel Protein Kinase Inhibitor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 199, no. 1, 28 February 1994 (1994-02-28), pages 93 - 98, XP024764939, ISSN: 0006-291X, [retrieved on 19940228] *

Also Published As

Publication number Publication date
WO2009111169A2 (fr) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2008054544A3 (fr) Procédé d'administration à travers la barrière hématoencéphalique
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2005099715A3 (fr) Traitement de pathologies ophtalmiques
MX2010003774A (es) Formulaciones oftalmicas acuosas.
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
WO2007150018A3 (fr) Implants intraoculaires à libération prolongée contenant des stéroïdes et procédés associés
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
WO2003014309A3 (fr) Recepteurs de l'interleukine-1 dans le traitement de maladies
IL188789A0 (en) Formulation and method for administration of ophthalmologically active agents
WO2007109097A3 (fr) modulation ARNi des TGF-beta et usages therapeutiques
WO2007038669A3 (fr) Composes et compositions contenant de la diarylamine, et utilisation en tant que modulateurs de recepteurs de c-kit
WO2007015739A3 (fr) Revetements pea-tempo/pea-bz permettant une administration controlee de medicaments a partir de dispositifs medicaux implantables
EP1933833B8 (fr) Therapie pour le traitement de la vessie hyperactive
WO2007002572A3 (fr) Nattokinase pour reduire la viscosite du sang total
WO2001030802A3 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines
WO2008070132A3 (fr) Procédés d'utilisation de modulateurs de récepteur trk
AU2017261303A1 (en) Ophthalmic compositions
WO2008048675A3 (fr) Traitement de la dégénération maculaire due au vieillissement et d'autres maladies oculaires
WO2005077122A3 (fr) Composes et compositions convenant comme modulateurs des lxr
WO2005009394A3 (fr) Administration de medicaments dans le systeme nerveux
WO2009089399A3 (fr) Compositions comprenant des antagonistes du récepteur ou du co-récepteur de type toll et procédés de neuroprotection oculaire
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
WO2005115432A3 (fr) Traitement de maladies et de troubles oculaires utilisant des compositions lantibiotiques
BR112012016128A2 (pt) agente terapêutico (y-39983) para disfunção endotelial da córnea
MX2007004861A (es) Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09718261

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09718261

Country of ref document: EP

Kind code of ref document: A2